Physician profile
Wesley Herman
NPI 1508863101
$4,044.53
in general payments reported to CMS, 2019-2025
30 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $370 · 2021: $1,014 · 2022: $749 · 2023: $432 · 2024: $908 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,473.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $693.75 | 2019-2023 | Catalys System |
| Alimera Sciences, INC. | $586.74 | 2024 | Iluvien, Yutiq |
| Mallinckrodt Hospital Products INC. | $344.75 | 2020-2022 | |
| Allergan, INC. | $339.05 | 2019-2022 | |
| Ocular Therapeutix, INC. | $285.18 | 2019-2025 | Dextenza |
| Abbvie INC. | $219.72 | 2022-2023 | |
| Alcon Vision LLC | $208.61 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Lensar, INC. | $193.18 | 2019 | |
| Biotissue Holdings INC. | $171.93 | 2020-2024 | |
| Kala Pharmaceuticals, INC. | $92.61 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $91.83 | 2021 | |
| Ani Pharmaceuticals, INC. | $76.81 | 2024 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $72.16 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Aerie Pharmaceuticals, INC. | $69.59 | 2019-2021 | |
| Beaver-Visitec International, INC. | $63.57 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $58.53 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $57.42 | 2021-2022 | |
| Oyster Point Pharma, INC. | $52.97 | 2022 | |
| Sun Pharmaceutical Industries INC. | $52.10 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $45.39 | 2024-2025 | Vyzulta |
| Mallinckrodt Enterprises LLC | $40.26 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $39.92 | 2024 | Xdemvy |
| Halozyme INC | $35.09 | 2021 | |
| Tearlab Corp | $28.70 | 2022-2023 | Tearlab Osmolarity System |
| Optos, INC. | $24.93 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $21.93 | 2024 | Callisto Eye |
| Dompe US, INC. | $20.15 | 2019 | |
| Ivantis, INC | $19.70 | 2021 | |
| Akorn, INC. | $19.01 | 2020 | |
| Notal Vision, INC. | $18.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.